Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.062 | 0.7 |